AVS Announces Additional $8.8M Series B
Summary
BOSTON, MA, AVS announced today that it closed an additional $8.8 million in new financing. AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL therapy, announced today that it closed an additional $8.8 million in new financing, bringing its Series B round to $28.8 million total. BioStar Capital, an investor in transformational medical technologies, led the Series B financing with CUE Growth Partners, a private equity firm focused on healthcare. AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It is redefining interventional therapy for severely calcified lesions with the Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device.